Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma

The predictors of response and survival in patients with hepatocellular carcinoma (HCC) receiving regorafenib remain unclear. This study aimed to delineate the determinants of response and survival after regorafenib and evaluate post-progression treatment and outcomes. We retrospectively enrolled 10...

Full description

Bibliographic Details
Main Authors:	Chao, Y. (Author), Chen, S.-C (Author), Chi, C.-T (Author), Hou, M.-C (Author), Huang, Y.-H (Author), Lee, I.-C (Author), Lee, P.-C (Author), Wu, C.-J (Author), Wu, K.-C (Author)
Format:	Article
Language:	English
Published:	MDPI 2022
Subjects:	hepatocellular carcinoma overall survival post-progression survival progression-free survival regorafenib sorafenib
Online Access:	View Fulltext in Publisher

Similar Items

Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study
by: Wang Y, et al.
Published: (2018-06-01)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
by: Wu J, et al.
Published: (2017-05-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)

Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
by: Issei Saeki, et al.
Published: (2021-05-01)

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)
by: Ioana Riaño, et al.
Published: (2020-07-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01)

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
by: Liyun Zheng, et al.
Published: (2021-01-01)

Progression-Free Survival Early Assessment is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
by: Giuseppe Cabibbo, et al.
Published: (2021-12-01)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
by: Hung-Wei Wang, et al.
Published: (2021-07-01)

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
by: Zhang E, et al.
Published: (2020-12-01)

Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma
by: Ye X, et al.
Published: (2018-11-01)

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
by: Piero Colombatto, et al.
Published: (2021-04-01)

Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
by: Qiu X, et al.
Published: (2020-09-01)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021-01-01)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020-08-01)

Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular CarcinomaSummary
by: Tomomi Hashiba, et al.
Published: (2020-01-01)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
by: Zou X, et al.
Published: (2021-05-01)

Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis
by: Cui R, et al.
Published: (2019-12-01)

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment
by: Ming‐Lun Yeh, et al.
Published: (2019-10-01)

Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
by: Taiga Otsuka, et al.
Published: (2015-05-01)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
by: Hisao Imai, et al.
Published: (2015-01-01)

Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma
by: Tae Hyun Kim, et al.
Published: (2020-04-01)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
by: Cicero G, et al.
Published: (2018-05-01)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
by: Forsythe A, et al.
Published: (2018-05-01)

Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study
by: Liu S, et al.
Published: (2019-02-01)

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
by: Leonardo Gomes da Fonseca, et al.
Published: (2018-12-01)

The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib
by: Fernanda Branco, et al.
Published: (2017-03-01)

Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
by: Huang Y, et al.
Published: (2019-01-01)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
by: Kasahara Norimitsu, et al.
Published: (2015-12-01)

Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy
by: Myung Jin Oh, et al.
Published: (2013-09-01)

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review
by: Oronzo Brunetti, et al.
Published: (2019-12-01)

Prognostic factors for progression‐free and overall survival in malignant pleural mesothelioma
by: Jordi Guzmán‐Casta, et al.
Published: (2021-04-01)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
by: Mohamed A. Abd El Aziz, et al.
Published: (2020-10-01)

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
by: Giovanni Marasco, et al.
Published: (2021-05-01)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
by: I-Chun Chen, et al.
Published: (2021-10-01)

Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib
by: Bin-Yan Zhong, et al.
Published: (2021-05-01)